Long-acting HIV drug arrives in Zimbabwe for high-risk groups

Zimbabwe has begun a donor-supported rollout of lenacapavir, a twice-yearly HIV prevention injection offered free to selected high-risk people.

Zimbabwe has launched lenacapavir, a long-acting HIV prevention injection given twice a year, in a donor-supported program aimed at people deemed at higher risk. The introduction follows clinical studies reported to show strong protection and is being discussed as a complement to existing prevention tools. The rollout is supported by PEPFAR and the Global Fund, and the drug was developed by Gilead Sciences. Officials note that funding and health system capacity will affect how broadly the drug can be offered. Key details: - The injection has been offered free in the initial phase to selected high-risk groups, including sex workers, adolescent girls and young women, gay men, and pregnant and breastfeeding women. - Zimbabwe expects about 46,000 people across 24 sites to benefit in the early phase of the rollout. - The program is donor-supported and the government has said it hopes to expand access as more donor-funded doses arrive. - Officials and advocates have warned that wider rollout depends on securing funds and addressing infrastructure and staffing limitations. Summary: Health officials say lenacapavir may help people who struggle with daily oral pills by providing a discreet, six-month prevention option. Expansion plans depend on additional doses and funding. Undetermined at this time.